Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein
- 15 March 2008
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (6), 2023-2027
- https://doi.org/10.1016/j.bmcl.2008.01.105
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating ProteinScience, 2007
- The 5 lipoxygenase system in the vasculature: Emerging role in health and diseaseMolecular and Cellular Endocrinology, 2006
- Regulation of 5-lipoxygenase enzyme activityBiochemical and Biophysical Research Communications, 2005
- Leukotriene modifiers as potential therapeutics for cardiovascular diseaseNature Reviews Drug Discovery, 2005
- Leukotriene Biosynthesis InhibitorsPublished by Elsevier BV ,2005
- Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized?European Journal of Medicinal Chemistry, 1999
- Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilizationBiochemistry, 1995
- The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivoJournal of Allergy and Clinical Immunology, 1995
- Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitorCanadian Journal of Physiology and Pharmacology, 1992